About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

For the quarter ended March 2024, Johnson & Johnson (JNJ) reported revenue of $21.38 billion, down 13.6% over the same period last year. EPS came in at $2.71, compared to $2.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $21.4 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +2.65%, with the consensus EPS estimate being $2.64.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

Key TakeawaysJohnson & Johnson shares slipped following the release of a first-quarter earnings report that included sales figures below estimates, but better-than-expected income.The company also increased its dividend, marking 62 straight years it has done so.Johnson & Johnson narrowed its full-year guidance, projecting increases to sales and adjusted earnings per share (EPS) of about 5% and 7%, respectively. Johnson & Johnson (JNJ) posted a mixed first-quarter earnings Tuesday, and raised its dividend wh ...

Key PointsJohnson & Johnson's mixed quarter revealed core strength and a widening margin. Guidance was raised with the mid-point for earnings above consensus. Analysts support this market and see it advancing at least 10%. 5 stocks we like better than Johnson & JohnsonShares of Johnson & Johnson NYSE: JNJ are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading near $145, JNJ stock is valued at less than 14X th ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.65%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.27 per share when it actually produced earnings of $2.29, delivering a surprise of 0.88%. Ov ...

st April 16, 2024 Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate o ...

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street's expectations as sales in its medical devices business surged.Meanwhile, the company's total revenue for the period was largely in line with estimates.J&J's medtech division provides devices for surgeries, orthopedics and vision. The company is benefiting from a rebound in demand for nonurgent surgeries among ol ...

Investors are always looking for stocks that are poised to beat at earnings season and Johnson & Johnson (JNJ) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Johnson & Johnson is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty ...

CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 bill ...

JHVEPhotoOverview Johnson & Johnson (NYSE:JNJ) has always been one of those companies that has a product and service offering so wide and large that JNJ can be considered its own healthcare ETF. Johnson & Johnson operates within the healthcare space with focus on some of the following segments: immunology, infections, neuroscience, and oncology to name a few. In addition, they also operate a segment called MedTech, that provides interventional solutions. With solid financials, a consistent dividend stre ...